IFI

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT Docket No. (Under 37 CFR 1.97(b) or 1.97(c)) RLL-265US In Re Application Of: CHAWLA et al. Application No. Filing Date Customer No. **Group Art Unit** Examiner Confirmation No. 12/6/2004 10/517,080 **TBA** 26,815 **TBA** 8568 Title: ED RELEASE ORAL DOSAGE FORMS OF GABAPENTIN NOV 0 6 2006 Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 37 CFR 1.97(b) The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114. 37 CFR 1.97(c) 2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: ☐ the statement specified in 37 CFR 1.97(e); OR □ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))						Docket No. RLL-265US	
Re Application of:	CHAWLA et al.						
Application No.	Filing Date	Examine	er	Customer No.	Group Art Unit	Confirmation No	
10/517,080	12/6/2004	TBA		26,815	TBA	8568	
NOV 0 6 2006 8		Paymolete if Applicant elec	ent of Fee				
as described  Char  Cred	is hereby authorized	e required.	edit Deposit A	ccount No.	50-0912		
WARNING: Included on	nformation on this this form. Provide of Transmission by	form may becom credit card inforn	e public. Cro nation and a	uthorization	rmation should on PTO-2038. ing by First Class	* mail &	
I certify that this do	ocument and authorization facsimile transmitted to	n to charge deposit	I hereby ce with the Uni as first c "Commission 22313-1450"	rtify that this conted States Postallass mail in the for Patents, F [37 CFR 1.8(a)] or 31, 2006  Date)  Signature of Pers	respondence is bein I Service with suffician envelope add P.O. Box 1450, Alexon	ng deposited ient postage dressed to kandria, VA	
Typed or Prin	ted Name of Person Signin	MICHELLE MORGAN  Typed or Printed Name of Person Mailing Certificate					
*This certificate deposit account  William D. H. Reg. No. 44,	<i>Usin Have</i> signature are 739	paying by		etober 31, 2006		пусате	

cc:

· •					Docket No.: R	LL-265US	Serial No.	: 10/517,080
INFORMATION DISCLOSURE CITATION				Applicants: CHAWLA et al.				
SUPPLEMENTAL SUPPLEMENTAL				Filed: 12/6/20	04	Group:		
13	- CUIF	8			(Side			
NOV CANADA	WE ST		U.S. P	ATENT	DOCUMENTS			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	S1A1	2002/107208	8/8/2002	Chen e	et al.	514	25	
	<u> </u>							
							-	William I The Control of the Control
	ļ						-	
	ļ							<del></del> -
			FOREIGN	N PATEN	IT DOCUMENT	S		
		DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSLATION YES   NO
	S1B1	WO 03/035177	5/1/2003	PCT		A61P		
	S1B2	WO 05/011666	2/10/2005	PCT		A61K	31/195	
	S1B3	WO 05/020978	3/10/2005	PCT		A61K	31/195	
	S1B4	WO 05/077332	8/25/2005	PCT		A61K	9/00	
					***			<u> </u>
								<u> </u>
		OTHER DOCUME	NTS (Includ	ding Auth	nor, Title, Date,	Pertinent P	ages, Etc.)	

- · ·		

**EXAMINER** 

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.